Skip to content
‹ Back to IndustriesSciences

What the Future Looks Like if We Get It Right

As the Patient Monitoring series concludes, the conversation shifts from today’s challenges to tomorrow’s possibilities. This final episode of the five-part Health and Life Sciences at the Edge series looks ahead to what healthcare could become if patient monitoring gets it right. Intel’s Kaeli Tully is joined by Sudha Yellapantula, Senior Researcher at Medical…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Michelle Dawn Mooney · · Ai in HealthcareAmbient MonitoringArtificial IntelligenceClinician Workflow
Share

Key takeaways

01

As the Patient Monitoring series concludes, the conversation shifts from today’s challenges to tomorrow’s possibilities.

02

This final episode of the five-part Health and Life Sciences at the Edge series looks ahead to what healthcare could become if patient monitoring gets it right.

03

Intel’s Kaeli Tully is joined by Sudha Yellapantula, Senior Researcher at Medical…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

As the Patient Monitoring series concludes, the conversation shifts from today’s challenges to tomorrow’s possibilities. This final episode of the five-part Health and Life Sciences at the Edge series looks ahead to what healthcare could become if patient monitoring gets it right. Intel’s Kaeli Tully is joined by Sudha Yellapantula, Senior Researcher at Medical Informatics Corp., with a special appearance from Bikram Day, Director of Informatics at Medical Informatics Corp., to explore bold predictions, personalized care, and the safeguards needed to responsibly build the future of healthcare.

Yellapantula grounds the conversation in real-world innovation, sharing projects that use physiological data to predict cardiac arrest, compare CPR techniques, and detect critical events through signal analysis alone. These experiences shape her vision for the future, where predictive analytics are deeply personalized. “All our predictive analytics should be personalized to us,” she explains. “Your history, your genetics, your past surgeries—really fine-tuning your model to you.”

Looking toward 2050, the episode imagines a healthcare system that is proactive rather than reactive. Yellapantula envisions universal monitoring on hospital entry, where wearables immediately screen for major events like strokes or heart attacks, and monitoring intensity adapts based on patient acuity. “You’re customizing your monitoring and producing the best prediction to be sent to the correct people,” she says, emphasizing the need to surface only the most relevant, actionable alerts without overwhelming clinicians.

The discussion also explores how clinician workflows could change. Instead of searching across fragmented systems, nurses and physicians would receive a comprehensive, centralized view of each patient’s physical, emotional, and psychological state. “Those logistical hassles should really be in the past,” Yellapantula notes. “We’ve gone to outer space. We can bring our healthcare system up to speed.”

Day expands the vision further, pointing to advances in wearable technology, biomarker detection, and multimodal AI. He predicts that future wearables will not only collect data but process it intelligently, flagging early warning signs and guiding patients toward timely intervention. “The cost to intervene is going to go down,” he says, making proactive care more accessible and equitable.

But with opportunity comes responsibility. One of the episode’s most critical lessons centers on data integrity. Yellapantula warns that poorly managed training data can undermine even the best AI models. “To build a good predictive model, you need good quality data and good quality labels,” she explains, urging the industry to address data contamination now before it becomes a limiting factor.

The episode closes with a clear takeaway: if patient monitoring succeeds, it enables earlier detection, smarter decisions, and more personalized care. “We’re able to have very actionable alerts where we really have the greatest impact on patient outcomes,” Yellapantula says. It’s a future built not just on better technology, but on better choices, collaboration, and trust.

Connect with the thought leaders driving this discussion:

Subscribe to this channel on Apple Podcasts and Spotify to hear more from the Intel Internet of Things Group.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

MD

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

IndexBox sees replacements driving a third of quantum cascade laser shipments by 2030

IndexBox sees replacements driving a third of quantum cascade laser shipments by 2030

The quantum cascade laser market is projected to grow 8% to 12% a year through 2035, driven by mid-infrared spectroscopy in process control, environmental monitoring and pharmaceutical quality checks. In these uses, the lasers offer high spectral brightness and run at room temperature in compact form factors. The installed base of analytical instruments is also growing.

  • 01Roughly one in three quantum cascade lasers shipped in 2030 is projected to replace equipment already in service, so maintenance calendars will set a growing share of demand.
  • 02For a plant or QA lab running QCL-based analyzers, the useful question is which laser maker sits inside each instrument and whether a second source exists.
  • 03Analyzers bought on a three-to-five-year cycle in 2026 come due between 2029 and 2031. Those years will show whether the forecast replacement wave turns up in real orders.

Oct 26, 2026

Why shared auto-injectors keep forcing rebuilt device files

Why shared auto-injectors keep forcing rebuilt device files

Vertex Knight co-founder Fubin Wu cites digitalization, personalization and large-volume delivery as trends reshaping drug delivery devices, arguing structured data can enable reuse and cut duplicated design-file work for shared auto-injectors. ISPE says no regulatory pathway exists for platform devices, and ONdrugDelivery counts 182 large-volume subcutaneous biologics, about 15% of IV and SC agents.

  • 01A device shared across drug products still triggers repeated design control work for each new combination product, and ISPE's November 2025 article says no regulatory pathway yet exists to approve a platform device.
  • 02FDA's May 2024 draft platform technology designation under section 506K is written for drug product applications, so device design files sit outside it.
  • 03Large-volume subcutaneous biologics above 2 mL numbered 182 in a January 2025 ONdrugDelivery review, about 15% of IV and SC agents; Advanced Drug Delivery Reviews reported in July 2026 that volumes up to 25 mL are now pursued.

Oct 22, 2026

Hepalink's FOYA-winning syringe plant inspects 24,000 units an hour

Hepalink's FOYA-winning syringe plant inspects 24,000 units an hour

Hepalink's Pingshan prefilled syringe plant in Shenzhen won the Innovation (Novel Technology) category at ISPE's 2026 Facility of the Year Awards. In the transcript ISPE posted with its podcast, CaiXue Wei describes vertical design, AGV-assisted transfer, AI inspection and 5G-MEC as one integrated system built around a 330 million-syringe annual capacity; Hepalink's own release adds a 24-meter warehouse, sub-10 millisecond 5G and 24,000-unit-an-hour inspection.

  • 01Hepalink's 24-meter automated warehouse raised space utilization 52 percent over a traditional layout on a land-scarce Shenzhen site supporting 330 million syringes a year.
  • 02AGVs pass material through vaporized hydrogen peroxide chambers straight into Grade A isolators, and Hepalink credits the zero-touch flow for a 100 percent first media fill.

Oct 22, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

MD
Michelle Dawn Mooney

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512